Effect of glass markings on drinking rate in social alcohol drinkers (study two)

This study investigated whether volume information on curved glasses alters the time taken to consume an alcoholic beverage. Participants (n = 160) were asked to drink standard strength lager from either a curved glass marked with ¼, ½, and ¾ volume points or an unmarked curved glass. Time to consume the drink was recorded

Effect of glass markings on drinking rate in social alcohol drinkers (study one)

This study investigated whether volume information on curved glasses alters the time taken to consume an alcoholic beverage. Participants (n = 159) were asked to drink low or standard strength lager from either a curved glass marked at midpoint with a band of yellow tape or an unmarked curved glass. Time to consume the drink was recorded. Data are restricted access for this study as participants were consented under procedures that did not include consent for data to be made open

Data from: Adjunctive clindamycin for cellulitis: clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis

Objective: To compare flucloxacillin with clindamycin to flucloxacillin alone for the treatment of limb cellulitis. Design: Parallel, double-blinded, randomised controlled trial. Setting: Emergency department attendances and general practice referrals within 20 hospitals in England. Interventions: Flucloxacillin, at a minimum of 500 mg 4 times per day for 5 days, with clindamycin 300 mg 4 times per day for 2 days given orally versus flucloxacillin given alone. Main outcome measures: The primary outcome was improvement at day 5. This was defined as being afebrile with either a reduction in affected skin surface temperature or a reduction in the circumference of the affected area. Secondary outcomes included resolution of systemic features, resolution of inflammatory markers, recovery of renal function, reduction in the affected area, decrease in pain, return to work or normal activities and the absence of increased side effects. Results: 410 patients were included in the trial. No significant difference was seen in improvement at day 5 for flucloxacillin with clindamycin (136/156, 87%) versus flucloxacillin alone (140/172, 81%)—OR 1.55 (95% CI 0.81 to 3.01), p=0.174. There was a significant difference in the number of patients with diarrhoea at day 5 in the flucloxacillin with clindamycin allocation (34/160, 22%) versus flucloxacillin alone (16/176, 9%)—OR 2.7 (95% CI 1.41 to 5.07), p=0.002. There was no clinically significant difference in any secondary outcome measures. There was no significant difference in the number of patients stating that they had returned to normal activities at the day 30 interview in the flucloxacillin with clindamycin allocation (99/121, 82%) versus flucloxacillin alone (104/129, 81%)—adjusted OR 0.90 (95% CI 0.44 to 1.84). Conclusions: The addition of a short course of clindamycin to flucloxacillin early on in limb cellulitis does not improve outcome. The addition of clindamycin doubles the likelihood of diarrhoea within the first few days.,C4C Anonymised DataThe data is derived form the paper forms completed for each patient within the study. The file contains expansions for each of the codes. for any further information please contact the lead author.C4CAnonFinalDataCheck1612.ods

The FRANK friends study: Data

This is data from The FRANK friends study. The protocol for the study can be found here: https://njl-admin.nihr.ac.uk/document/download/2031358 The dataset is saved and uploaded as a stata dta file. The associated metadata is uploaded as an excel workbook (FF_Metadata v1.0.xlsv). It has the column headings of: variable name, variable label (containing the question), data type, value, value labels, variable length, missing code, display format, validation type, information on anonymisation and source questions. Any uses of this dataset must acknowlegde the funder using the text: "This work was supported by the National Institute of Health Research (NIHR) Public Health Research programme, grant number NIHR PHR 17/97/02.

The FRANK friends study: Data

This is data from The FRANK friends study. The protocol for the study can be found here: https://njl-admin.nihr.ac.uk/document/download/2031358 The dataset is saved and uploaded as a stata dta file. The associated metadata is uploaded as an excel workbook (FF_Metadata v1.0.xlsv). It has the column headings of: variable name, variable label (containing the question), data type, value, value labels, variable length, missing code, display format, validation type, information on anonymisation and source questions. Any uses of this dataset must acknowlegde the funder using the text: "This work was supported by the National Institute of Health Research (NIHR) Public Health Research programme, grant number NIHR PHR 17/97/02.

Data from: The burden of Hepatitis C virus infection in Punjab, India: a population-based serosurvey

Introduction: Hepatitis C virus (HCV) infection prevalence is believed to be elevated in Punjab, India; however, state-wide prevalence data are not available. An understanding of HCV prevalence, risk factors and genotype distribution can be used to plan control measures in Punjab. Methods: A cross-sectional, state-wide, population-based serosurvey using a multi-stage stratified cluster sampling design was conducted October 2013 to April 2014. Children aged >5 years and adults were eligible to participate. Demographic and risk behavior data were collected, and serologic specimens were obtained and tested for anti-HCV antibody, HCV Ribonucleic acid (RNA) on anti-HCV positive samples, and HCV genotype. Prevalence estimates and adjusted odds ratios for risk factors were calculated from weighted data and stratified by urban/rural residence. Results: 5,543 individuals participated in the study with an overall weighted anti-HCV prevalence of 3.6% (95% Confidence Interval [CI]: 3.0%-4.2%) and chronic infection (HCV Ribonucleic acid test positive) of 2.6% (95% CI: 2.0%-3.1%). Anti-HCV was associated with being male (adjusted odds ratio 1.52; 95% CI: 1.08-2.14), living in a rural area (adjusted odds ratio 2.53; 95% CI: 1.62-3.95) and was most strongly associated with those aged 40-49 (adjusted odds ratio 40-49 vs 19-29-year-olds 3.41; 95% CI: 1.90-6.11). Anti-HCV prevalence increased with each blood transfusion received (adjusted odds ratio 1.36; 95% CI: 1.10-1.68) and decreased with increasing education, (adjusted odds ratio 0.37 for graduate-level vs. primary school/no education; 95% CI: 0.16-0.82). Genotype 3 (58%) was most common among infected individuals. Discussion: The study findings, including the overall prevalence of chronic HCV infection, associated risk factors and demographic characteristics, and genotype distribution can guide prevention and control efforts, including treatment provision. In addition to high-risk populations, efforts targeting rural areas and adults aged >40 would be the most effective for identifying infected individuals.,punjab_dryad_cleanerThis is a Stata version 15.1 dta file that contains data from the 2013-2014 Punjab (India) population serosurvey on hepatitis C virus. Note that variables have been cut from the dataset due to Dryad's rules on data confidentiality.

Data from: The burden of Hepatitis C virus infection in Punjab, India: a population-based serosurvey

Introduction: Hepatitis C virus (HCV) infection prevalence is believed to be elevated in Punjab, India; however, state-wide prevalence data are not available. An understanding of HCV prevalence, risk factors and genotype distribution can be used to plan control measures in Punjab. Methods: A cross-sectional, state-wide, population-based serosurvey using a multi-stage stratified cluster sampling design was conducted October 2013 to April 2014. Children aged >5 years and adults were eligible to participate. Demographic and risk behavior data were collected, and serologic specimens were obtained and tested for anti-HCV antibody, HCV Ribonucleic acid (RNA) on anti-HCV positive samples, and HCV genotype. Prevalence estimates and adjusted odds ratios for risk factors were calculated from weighted data and stratified by urban/rural residence. Results: 5,543 individuals participated in the study with an overall weighted anti-HCV prevalence of 3.6% (95% Confidence Interval [CI]: 3.0%-4.2%) and chronic infection (HCV Ribonucleic acid test positive) of 2.6% (95% CI: 2.0%-3.1%). Anti-HCV was associated with being male (adjusted odds ratio 1.52; 95% CI: 1.08-2.14), living in a rural area (adjusted odds ratio 2.53; 95% CI: 1.62-3.95) and was most strongly associated with those aged 40-49 (adjusted odds ratio 40-49 vs 19-29-year-olds 3.41; 95% CI: 1.90-6.11). Anti-HCV prevalence increased with each blood transfusion received (adjusted odds ratio 1.36; 95% CI: 1.10-1.68) and decreased with increasing education, (adjusted odds ratio 0.37 for graduate-level vs. primary school/no education; 95% CI: 0.16-0.82). Genotype 3 (58%) was most common among infected individuals. Discussion: The study findings, including the overall prevalence of chronic HCV infection, associated risk factors and demographic characteristics, and genotype distribution can guide prevention and control efforts, including treatment provision. In addition to high-risk populations, efforts targeting rural areas and adults aged >40 would be the most effective for identifying infected individuals.,punjab_dryad_cleanerThis is a Stata version 15.1 dta file that contains data from the 2013-2014 Punjab (India) population serosurvey on hepatitis C virus. Note that variables have been cut from the dataset due to Dryad's rules on data confidentiality.

sj-xlsx-3-jrs-10.1177_01410768231184162 - Supplemental material for Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults

Supplemental material, sj-xlsx-3-jrs-10.1177_01410768231184162 for Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults by Catherine Hyams, George Qian, George Nava, Robert Challen, Elizabeth Begier, Jo Southern, Maria Lahuerta, Jennifer L Nguyen, Jade King, Anna Morley, Madeleine Clout, Nick Maskell, Luis Jodar, Jennifer Oliver, Gillian Ellsbury, John M McLaughlin, Bradford D Gessner, Adam Finn, Leon Danon, James W Dodd and The Avon CAP Research Group in Journal of the Royal Society of Medicin